Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;2003(1):CD003574.
doi: 10.1002/14651858.CD003574.pub2.

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

A K Akobeng  1 , M Zachos
Affiliations

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

A K Akobeng et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: Crohn's disease may be refractory to conventional treatments such as corticosteroids, enteral nutrition and immuno-suppressive agents. A number of patients with the disease may also become steroid-dependent leading to increased risk of developing steroid-related adverse effects. Recent studies suggest that TNF-a blocking agents may be effective in inducing remission in Crohn's disease.

Objectives: To conduct a systematic review to evaluate the effectiveness of TNF-a blocking agents in inducing remission in patients with active Crohn's disease.

Search strategy: We searched MEDLINE (1966-June 2003), EMBASE (1984-June 2003), the Cochrane Central Register of Controlled Trials from the Cochrane Library (Issue 2, 2003) and the IBD Review Group Specialized Trials Register. We hand-searched the articles cited in each publication obtained.

Selection criteria: We included only randomised controlled trials in which patients with active Crohn's disease (defined by a validated Crohn's disease activity index) were randomly allocated to receive a TNF-a blocking agent in the treatment arm, or to receive placebo or another treatment in the comparison arm.

Data collection and analysis: Data extraction and assessment of the methodological quality of each trial were independently performed by two reviewers. Any disagreement among reviewers was resolved by consensus. Outcome measures reported in the primary studies included clinical remission, clinical response and changes in disease activity index.

Main results: Ten studies were identified of which 4 met the inclusion criteria. The included studies either differed in the type of TNF-a blocking agent used or in the way outcomes were assessed to such an extent that we considered it inappropriate to combine the data statistically. There is evidence from one randomised controlled trial that suggests that a single intravenous infusion of the monoclonal antibody cA2, infliximab, may be effective for induction of remission in Crohn's disease. There was no difference in response rates among infliximab doses of 5, 10 or 20 mg/kg. The results of two other trials suggested that CDP571, the genetically engineered human TNF monoclonal antibody, may also be effective in reducing disease activity index at 2 weeks after an infusion. We did not find any evidence to support the use of etanercept in Crohn's disease.

Reviewer's conclusions: Evidence from one randomized controlled trial suggests that a single infusion of infliximab may be effective for induction of remission in Crohn's disease. Based on this study, we can recommend a dose of 5 mg/kg. There is also some evidence that CDP571 may be effective in inducing remission in Crohn's disease. We did not find any evidence that supports the use of etanercept in Crohn's disease. The period of follow up for the patients in these studies was probably too short to allow adequate assessment of recently reported serious adverse effects such as tuberculosis and lymphoma.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Infliximab versus placebo, Outcome 1 Remission rate.
1.2
1.2. Analysis
Comparison 1 Infliximab versus placebo, Outcome 2 Clinical Response.
2.1
2.1. Analysis
Comparison 2 CDP571 versus placebo, Outcome 1 Remission rate.
2.2
2.2. Analysis
Comparison 2 CDP571 versus placebo, Outcome 2 Clinical Response.
3.1
3.1. Analysis
Comparison 3 Etanercept versus placebo, Outcome 1 Remission rate.
3.2
3.2. Analysis
Comparison 3 Etanercept versus placebo, Outcome 2 Clinical response.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD003574

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Sandborn 2001a {published data only}
    1. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm M, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double‐blind placebo‐controlled trial. Gastroenterology 2001;120:1330‐8. - PubMed
Sandborn 2001b {published data only}
    1. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: A randomized double‐blind, placebo‐controlled trial. Gastroenterology 2001;121:1088‐94. - PubMed
Stack 1997 {published data only}
    1. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor‐alpha in Crohn's disease. Lancet 1997;349:521‐4. - PubMed
Targan 1997 {published data only}
    1. Targan SR, Hanauer SB, Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029‐35. - PubMed

References to studies excluded from this review

Baldassano 2003 {published data only}
    1. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan G, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833‐8. - PubMed
D'Haens 1999 {published data only}
    1. D'Haens G, Deventer S, Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histologic healing with infliximab anti‐tumor Necrosis factor antibodies in Crohn's Disease: a European multicentre trial. Gastroenterology 1999;116:1029‐34. - PubMed
Hanauer 2002 {published data only}
    1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541‐9. - PubMed
Present 1999 {published data only}
    1. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398‐405. - PubMed
Rutgeerts 1999 {published data only}
    1. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti‐tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761‐9. - PubMed
Rutgeerts 2003 {published data only}
    1. Rutgeerts P, Lemmens L, Assche G, Noman M, Borghini‐Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open label study. Aliment Pharmacol Ther 2003;17:185‐92. - PubMed

Additional references

Baert 1999
    1. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down‐regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22‐8. - PubMed
Bauditz 1997
    1. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470‐4. - PMC - PubMed
Bell 2000
    1. Bell SJ, Kamm MA. Review article: the clinical role of anti‐TNF alpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000;14:501‐14. - PubMed
Breese 1994
    1. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor ‐alpha producing cells in the intestinal musosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455‐66. - PubMed
Brown 2002
    1. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty‐six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151‐8. - PubMed
Clarke 2001
    1. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4, 2001. Oxford : Update software. Updated quarterly.
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996;17:1‐12. - PubMed
Keane 2001
    1. Keane J, Gershon S, Wise RP, Mirabile‐Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha‐neutralizing agent. N Engl J Med 2001;345:1098‐104. - PubMed
MacDonald 1990
    1. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor‐alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301‐5. - PMC - PubMed
Murch 1991
    1. Murch SH, Lamkin VA, Savage MO, Walker Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor‐alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913‐7. - PMC - PubMed
Papadikas 2000
    1. Papadikas KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterolgy 2000;119:1148‐57. - PubMed
Pitkin 1999
    1. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:1110‐1. - PubMed
Rampton 1999
    1. Rampton DS. Management of Crohn's disease. BMJ 1999;319:1480‐5. - PMC - PubMed
Reimund 1996
    1. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al. Increased production of tumour necrosis factor‐a, interleukin 1b, and interleukin‐6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684‐9. - PMC - PubMed
Scallon 1995
    1. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti TNF‐ alpha monoclonal antibody Ca2 binds recombinant trasmembrane TNF‐ alpha and activates immune effector functions. Cytokine 1995;7:251‐9. - PubMed
Shanahan 2001
    1. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology 2001;120:622‐35. - PubMed
Siegel 1995
    1. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF‐ lethality in vivo. Cytokine 1995;7:15‐25. - PubMed

Publication types

MeSH terms